Avodart prostate cancer lawsuit

The FDA has issued a warning of an increased risk of high-grade prostate cancer with Avodart (generic:dutasteride), currently approved to treat benign adenofibromyomatous hyperplasia or BPH.

This risk appears to be low, but healthcare professionals should be aware of this safety information, and weigh the known benefits against the potential risks when deciding to start or continue treatment with 5-ARIs in men.

According to the U.S. Food and Drug Administration, Avodart inhibits the activity of the enzymes known as 5-alpha reductases. This prevents conversion of the hormone testosterone to another hormone called dihydrotesterone, which is necessary for normal development of male genitalia.

According to the Mayo Clinic, prostate cancers with Gleason scores of 8-10 are more likely to grow and spread quickly. The FDA’s warning were based on two large, randomized controlled studies. The trials found an overall reduction in the lower risk group, but an increased risk of the more dangerous form of the disease.

If you were diagnosed with prostate cancer Gleason score 8-10 after taking Avodart, then you may be eligible for compensation.

Fill out the form to arrange a free and confidential consultation to determine if you have a claim.